Michigan experience using the Tigertriever device to remove brain clots
Michigan Initial Experience Using Tigertriever for Thrombectomy
This project tries to see if the Tigertriever device safely and effectively removes large brain clots in adults who have an ischemic stroke within 8 hours of symptom onset.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Trial ID | NCT07363525 on ClinicalTrials.gov |
What this trial studies
This is an observational, real-world collection of outcomes from patients with large vessel occlusion who are treated with the Tigertriever device as first-line mechanical thrombectomy at Henry Ford Hospital. Treatment follows standard of care and no experimental procedures are added; researchers will collect procedural and safety data and a clinical follow-up visit at 3 months. Key data include restoration of blood flow after clot removal, procedure-related complications such as hemorrhage, and functional status at follow-up. Eligible patients are adults with LVO treated with Tigertriever, excluding those with acute hemorrhage on imaging, recent stroke/hemorrhage/thrombolysis/endovascular therapy within 3 months, or significant pre-stroke disability.
Who should consider this trial
Good fit: Adults (age ≥18) admitted with a large vessel occlusion ischemic stroke who are treated with the Tigertriever as the first-line thrombectomy device and can provide informed consent are ideal candidates.
Not a fit: Patients with acute intracranial hemorrhage on admission imaging, recent stroke/hemorrhage/thrombolysis or endovascular therapy within 3 months, significant pre-stroke disability (mRS ≥2), or those not treated with Tigertriever are unlikely to benefit from inclusion.
Why it matters
Potential benefit: If successful, the data could support that the Tigertriever is a safe and effective option for removing large clots and improving recovery after ischemic stroke.
How similar studies have performed: Mechanical thrombectomy with stent-retriever devices has been proven effective in large trials, and smaller reports of newer devices like Tigertriever have shown promising but more limited experience.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication. 2. Tigertriever was used as the first line treatment in the target vessel. 3. A signed informed consent. 4. Age ≥ 18. Exclusion Criteria: -1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months. 3\. pre-stroke disability (pre-stroke mRS ≥ 2).
Where this trial is running
Detroit, Michigan
- Henry Ford Hospital — Detroit, Michigan, United States (Recruiting)
Study contacts
- Study coordinator: Alex Chebl, MD
- Email: achebl1@hfhs.org
- Phone: 313-916-2644
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.